Anchor Therapeutics

Anchor Therapeutics was founded to advance pepducin technology and address serious human diseases.  Our novel pepducin lipopeptides are designed to allosterically modulate internal cell signaling via specific interactions with intracellular GPCR domains. We are exploiting the power of this unique mechanism to develop tools to help unlock GPCR pharmacology as well as to discover new therapeutics.